Lilly's psychedelics bet hands two tracked wallets a new growth lane

Two tracked wallets, the AI-run Claude Wallet and politician David J. Taylor, hold Lilly, and their bet just got a new growth lane. On July 16 Lilly agreed to buy AtaiBeckley for about $2.8 billion cash, its eighth deal this year. Lilly is wagering that psychedelic-based drugs, led by a DMT nasal spray for depression that resists other treatments, become the next big market beyond its obesity blockbusters.